Abstract 13183: The Burden of Uncontrolled Hypertension (HTN) in Chronic Kidney Disease (CKD). Impact of the Revised KDIGO Guidelines
Richard McGregor, Y Fred F Yang, James McCabe, Bill Cacheris- Physiology (medical)
- Cardiology and Cardiovascular Medicine
Introduction: The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease for patients not receiving dialysis highlights the increasing awareness of controlling HTN in CKD patients.
Goals/Aims: To identify the number of persons in the US with HTN and advanced CKD.
Research Question: Determine the current number of persons with advanced CKD and HTN based on various blood pressure thresholds and to project the increase in the number of patients over the next 10 years.
Methods: The analysis is based on multiple years of the US National Health and Nutrition Examination Survey (NHANES).
Results: We examined and projected the prevalence, awareness and treated number of HTN patients as well as the number of patients with uncontrolled HTN. Uncontrolled HTN was defined as taking at least 2 or more anti-hypertensive medications and the analysis focused on advanced CKD patients not requiring dialysis (stage 3b/4). Lowering the systolic/diastolic blood pressure threshold (mm Hg) from >140/90 to >130/80 or > 120/70 shows significant current numbers of patients with uncontrolled HTN and advanced kidney disease of 1.5 MM, 2.0 MM, and 2.7 MM, respectively. The number of patients is expected to increase 20% in the next 10 years highlighting the need for effective management of HTN in CKD.